Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Net Income (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Net Income for 11 consecutive years, with -$117.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income changed N/A to -$117.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$120.2 million, a N/A change, with the full-year FY2025 number at -$153.9 million, down 293.67% from a year prior.
  • Net Income was -$117.9 million for Q4 2025 at Crescent Biopharma, down from -$2.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$2.3 million in Q1 2025 to a low of -$117.9 million in Q4 2025.
  • A 5-year average of -$17.6 million and a median of -$10.7 million in 2024 define the central range for Net Income.
  • Peak YoY movement for Net Income: plummeted 86.28% in 2021, then surged 78.17% in 2025.
  • Crescent Biopharma's Net Income stood at -$17.4 million in 2021, then soared by 41.2% to -$10.2 million in 2022, then rose by 11.38% to -$9.1 million in 2023, then fell by 21.71% to -$11.0 million in 2024, then crashed by 966.82% to -$117.9 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Net Income are -$117.9 million (Q4 2025), -$2.3 million (Q1 2025), and -$11.0 million (Q3 2024).